A ONCE-DAILY ORAL JAK inhibitor indicated for the treatment of adults and pediatric patients 12+ years of age with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable.1

SKIN CLEARANCE AND ITCH REDUCTION TO

DISRUPT

THE ITCH AND RASH OF ATOPIC DERMATITIS

SKIN CLEARANCE DATA

Proportion of patients achieving EASI 75 skin clearance

Rapid, controlled skin clearance at Week 161,2*

Chart showing EASI 75 at Week 16 in the Measure Up 1 trial.
Chart showing EASI 75 at Week 16 in the Measure Up 2 trial.
  Placebo (n=281)
  RINVOQ 15 mg (n=281)
  RINVOQ 30 mg (n=285)

*Monotherapy results. †p≤0.001; RINVOQ vs placebo. NRI-C; ITT.

  Placebo (n=278)
  RINVOQ 15 mg (n=276)
  RINVOQ 30 mg (n=282)

*Monotherapy results. †p≤0.001; RINVOQ vs placebo. NRI-C; ITT.

RECOMMENDED DOSAGE IN AD1:

  • 30 mg is not an approved starting dose
  • For 12 to <65 years: Initiate with 15 mg once daily. If an adequate response is not achieved, consider increasing dosage to 30 mg once daily. Discontinue if an adequate response is not achieved with 30 mg dose. Use the lowest effective dose needed to maintain response
  • For 65+ years: Recommended dosage is 15 mg once daily

The co-primary endpoints1

were the percentage of patients achieving EASI 75 and a vIGA score of 0/1 at Week 16

vIGA 0/1 at Week 161,2:

8%Placebo

48%RINVOQ 15 mg

62%RINVOQ 30 mg

RECOMMENDED DOSAGE IN AD1:

  • 30 mg is not an approved starting dose
  • For 12 to <65 years: Initiate with 15 mg once daily. If an adequate response is not achieved, consider increasing dosage to 30 mg once daily. Discontinue if an adequate response is not achieved with 30 mg dose. Use the lowest effective dose needed to maintain response
  • For 65+ years: Recommended dosage is 15 mg once daily

THE CO-PRIMARY ENDPOINTS1

were the percentage of patients achieving EASI 75 and a vIGA score of 0/1 at Week 16

vIGA 0/1 at Week 161,2:

5%Placebo

39%RINVOQ 15 mg

52%RINVOQ 30 mg

Durable skin clearance rates at Week 52 in a blinded extension study5,6*

INTEGRATED RESULTS FROM MEASURE UP 1 AND 2;
ALL DATA ARE OBSERVED CASES

Chart showing EASI 75 skin clearance at Week 52 with RINVOQ® in a blinded to dose extension study.
  Placebo
  RINVOQ 15 mg
  RINVOQ 30 mg

*Monotherapy results. OC; ITT. Data are a sub-analysis of the MEASURE UP blinded extension data including only patients who were originally randomized to RINVOQ, completed the RCT, and enrolled in the blinded extension.

RECOMMENDED DOSAGE IN AD1:

  • 30 mg is not an approved starting dose
  • For 12 to <65 years: Initiate with 15 mg once daily. If an adequate response is not achieved, consider increasing dosage to 30 mg once daily. Discontinue if an adequate response is not achieved with 30 mg dose. Use the lowest effective dose needed to maintain response
  • For 65+ years: Recommended dosage is 15 mg once daily

DATA LIMITATIONS: Data through Week 52 were prespecified, non-ranked endpoints, not controlled for multiplicity; results cannot be considered statistically significant.

OLE LIMITATIONS: There is potential for enrichment of OLE data, as those who remain in the study are aware of their treatment and generally fare better than those who discontinue. Patients may have used topical medications.

Proportion of patients achieving EASI 90 skin clearance

Robust EASI 90 skin clearance measured at Week 161,2*

Chart showing EASI 90 at Week 16 in the Measure Up 1 trial.
Chart showing EASI 90 at Week 16 in the Measure Up 2 trial.
  Placebo (n=281)
  RINVOQ 15 mg (n=281)
  RINVOQ 30 mg (n=285)

*Monotherapy results. p≤0.001; RINVOQ vs placebo. NRI-C; ITT.

  Placebo (n=278)
  RINVOQ 15 mg (n=276)
  RINVOQ 30 mg (n=282)

*Monotherapy results. p≤0.001; RINVOQ vs placebo. NRI-C; ITT.

RECOMMENDED DOSAGE IN AD1:

  • 30 mg is not an approved starting dose
  • For 12 to <65 years: Initiate with 15 mg once daily. If an adequate response is not achieved, consider increasing dosage to 30 mg once daily. Discontinue if an adequate response is not achieved with 30 mg dose. Use the lowest effective dose needed to maintain response
  • For 65+ years: Recommended dosage is 15 mg once daily

THE CO-PRIMARY ENDPOINTS1

were the percentage of patients achieving EASI 75 and a vIGA score of 0/1 at Week 16

RANKED SECONDARY ENDPOINT1

included percentage of patients achieving EASI 90 at Week 16

vIGA 0/1 AT WEEK 161,2:

8%Placebo

48%RINVOQ 15 mg

62%RINVOQ 30 mg

RECOMMENDED DOSAGE IN AD1:

  • 30 mg is not an approved starting dose
  • For 12 to <65 years: Initiate with 15 mg once daily. If an adequate response is not achieved, consider increasing dosage to 30 mg once daily. Discontinue if an adequate response is not achieved with 30 mg dose. Use the lowest effective dose needed to maintain response
  • For 65+ years: Recommended dosage is 15 mg once daily

THE CO-PRIMARY ENDPOINTS1

were the percentage of patients achieving EASI 75 and a vIGA score of 0/1 at Week 16

RANKED SECONDARY ENDPOINT1

included percentage of patients achieving EASI 90 at Week 16

vIGA 0/1 AT WEEK 161,2:

5%Placebo

39%RINVOQ 15 mg

52%RINVOQ 30 mg

Durable skin clearance rates at Week 52 in a blinded extension study5,6*

INTEGRATED RESULTS FROM MEASURE UP 1 AND 2;
ALL DATA ARE OBSERVED CASES

Chart showing EASI 90 skin clearance at Week 52 with RINVOQ® in a blinded to dose extension study.
  Placebo
  RINVOQ 15 mg
  RINVOQ 30 mg

*Monotherapy results. OC; ITT. Data are a sub-analysis of the MEASURE UP blinded extension data including only patients who were originally randomized to RINVOQ, completed the RCT, and enrolled in the blinded extension.

RECOMMENDED DOSAGE IN AD1:

  • 30 mg is not an approved starting dose
  • For 12 to <65 years: Initiate with 15 mg once daily. If an adequate response is not achieved, consider increasing dosage to 30 mg once daily. Discontinue if an adequate response is not achieved with 30 mg dose. Use the lowest effective dose needed to maintain response
  • For 65+ years: Recommended dosage is 15 mg once daily

DATA LIMITATIONS: Data through Week 52 were prespecified, non-ranked endpoints, not controlled for multiplicity; thus, results cannot be considered statistically significant.

OLE LIMITATIONS: There is potential for enrichment of OLE data, as those who remain in the study are aware of their treatment and generally fare better than those who discontinue. Patients may have used topical medications.

Visible results at Week 16 with RINVOQ3

EASI 75
(Co-primary endpoint)1
Patient Results Week 16

Patient 1: Legs

Legs after the treatment at 16 weeks.
Legs before the treatment.

BASELINE

EASI: 42

WEEK 16

EASI: 8.4

Patient 2: Right arm

Arms after the treatment at 16 weeks.
Arms before the treatment.

BASELINE

EASI: 21.4

WEEK 16

EASI: 4.4

Actual MEASURE UP patients treated with RINVOQ (15 mg) in a clinical trial. Individual results may vary.

EASI 90
(Ranked secondary endpoint)2
Patient Results EASI 90

Patient 3: Back

Back after the treatment at 16 weeks.
Back before the treatment.

BASELINE

EASI: 43.7

WEEK 16

EASI: 1.6

Patient 3: Left arm

Arms after the treatment at 16 weeks.
Arms before the treatment.

BASELINE

EASI: 43.7

WEEK 16

EASI: 1.6

Actual MEASURE UP patient treated with RINVOQ (15 mg) in clinical trials. Individual results may vary.

EASI=Eczema Area and Severity Index.

EASI 75=improvement of at least 75% in lesion extent and severity.

EASI 90=improvement of at least 90% in lesion extent and severity.

ITCH RELIEF DATA

Proportion of patients with improvement in worst pruritus NRS ≥4

Rapid, controlled itch relief at
Week 161,2*

Chart showing itch relief at Week 16 in the Measure Up 1 trial. Chart showing itch relief at Week 16 in the Measure Up 1 trial. Chart showing itch relief at Week 16 in the Measure Up 1 trial.
Chart showing itch relief at Week 16 in the Measure Up 2 trial. Chart showing itch relief at Week 16 in the Measure Up 2 trial. Chart showing itch relief at Week 16 in the Measure Up 2 trial.
  Placebo (n=272)
  RINVOQ 15 mg (n=274)
  RINVOQ 30 mg (n=280)

*Monotherapy results. p≤0.001; RINVOQ vs placebo. NRI-C; ITT.

  Placebo (n=274)
  RINVOQ 15 mg (n=270)
  RINVOQ 30 mg (n=280)

*Monotherapy results. p≤0.001; RINVOQ vs placebo. NRI-C; ITT.

RECOMMENDED DOSAGE IN AD1:

  • 30 mg is not an approved starting dose
  • For 12 to <65 years: Initiate with 15 mg once daily. If an adequate response is not achieved, consider increasing dosage to 30 mg once daily. Discontinue if an adequate response is not achieved with 30 mg dose. Use the lowest effective dose needed to maintain response
  • For 65+ years: Recommended dosage is 15 mg once daily

THE CO-PRIMARY ENDPOINTS1

were the percentage of patients achieving EASI 75 and a vIGA score of 0/1 at Week 16

RANKED SECONDARY ENDPOINT2

RESPONSES OBSERVED AS EARLY AS

2 DAYSafter 1st dose:

16%RINVOQ 15 mg (n=275)

3%Placebo (n=270)

RECOMMENDED DOSAGE IN AD1:

  • 30 mg is not an approved starting dose
  • For 12 to <65 years: Initiate with 15 mg once daily. If an adequate response is not achieved, consider increasing dosage to 30 mg once daily. Discontinue if an adequate response is not achieved with 30 mg dose. Use the lowest effective dose needed to maintain response
  • For 65+ years: Recommended dosage is 15 mg once daily

THE CO-PRIMARY ENDPOINTS1

were the percentage of patients achieving EASI 75 and a vIGA score of 0/1 at Week 16

RANKED SECONDARY ENDPOINT2

RESPONSES OBSERVED AS EARLY AS

2 DAYSafter 1st dose:

12%RINVOQ 15 mg (n=269)

3%Placebo (n=267)

Durable rates of itch relief at Week 52 in a blinded extension study5,6*

INTEGRATED RESULTS FROM MEASURE UP 1 AND 2;
ALL DATA ARE OBSERVED CASES

Chart showing itch relief at Week 52 in a blinded to dose extension study. Chart showing itch relief at Week 52 in a blinded to dose extension study. Chart showing itch relief at Week 52 in a blinded to dose extension study.
  Placebo
  RINVOQ 15 mg
  RINVOQ 30 mg

*Monotherapy results. OC; ITT. Data are a sub-analysis of the MEASURE UP blinded extension data including only patients who were originally randomized to RINVOQ, completed the RCT, and enrolled in the blinded extension.

RECOMMENDED DOSAGE IN AD1:

  • 30 mg is not an approved starting dose
  • For 12 to <65 years: Initiate with 15 mg once daily. If an adequate response is not achieved, consider increasing dosage to 30 mg once daily. Discontinue if an adequate response is not achieved with 30 mg dose. Use the lowest effective dose needed to maintain response
  • For 65+ years: Recommended dosage is 15 mg once daily

DATA LIMITATIONS: Data through Week 52 were prespecified, non-ranked endpoints, not controlled for multiplicity; thus, results cannot be considered statistically significant.

OLE LIMITATIONS: There is potential for enrichment of OLE data, as those who remain in the study are aware of their treatment and generally fare better than those who discontinue. Patients may have used topical medications.

Rates of worst pruritus NRS 0/1 observed at Week 164

Poll results icon.

Interested in what patients experienced with RINVOQ in clinical trials?

Want to know if RINVOQ is an option for your patients?

Are your patients seeking treatment for the rash of atopic dermatitis?

Is itch a primary concern?

Safety is important to you. Want to know more about the safety
profile of RINVOQ?

Want to know more about monitoring guidelines for RINVOQ?

RINVOQ® Complete can help patients get the support they need
to start and stay on track with their prescribed treatment.

Familiar with Complete? RINVOQ Complete offers the same
exceptional AbbVie support you know and trust.

Want to discuss clinical trial data?

ONE PILL,

ONCE-DAILY 1

RINVOQ® (upadacitinib) packaging. RINVOQ® (upadacitinib) packaging. RINVOQ® (upadacitinib) packaging.

For adults <65 years and pediatric patients 12+ years weighing at least 40 kg (88 lb), initiate treatment with RINVOQ 15 mg once-daily in pediatric patients (≥12 years, ≥40 kg) and adults <65 years of age. If an adequate response is not achieved, consider increasing the dosage to 30 mg once-daily. Discontinue RINVOQ if an adequate response is not achieved with the 30 mg dose. Use the lowest effective dose needed to maintain response. For patients ≥65 years, patients receiving strong CYP3A4 inhibitors, and patients with severe renal impairment, the recommended dose of RINVOQ is 15 mg once-daily.1